GEA, G-CON, and Pfizer Collaborate on Continuous Manufacturing Process - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

GEA, G-CON, and Pfizer Collaborate on Continuous Manufacturing Process



GEA Process Engineering and G-CON Manufacturing have entered into a collaboration with Pfizer to develop PCMM (portable, continuous, miniature, and modular) manufacturing to address the rapidly changing requirements of pharmaceutical development and manufacturing, GEA and G-CON announced in a press release. A preliminary engineering study has already been completed, and the new collaboration will focus on the fabrication and qualification of a prototype unit.

The goal of the collaboration is to create a system that integrates small-footprint, continuous/semi-continuous processing equipment; smart control systems; and self-contained GMP facility modules, known as PODs, to process API powders and inactive ingredients through to bulk tablets or capsules. PODs, which are portable and can be rapidly deployed, are a cost-effective alternative to large, highly capitalized manufacturing facilities with fixed equipment and limited flexibility. This first-of-a-kind system would have the potential to transform the future of pharmaceutical process development and manufacturing while providing the flexibility needed to address the evolving portfolio requirements for in-country and small-lot manufacturing. Additionally, it would have the potential to allow product development, clinical supply manufacture, and commercialization to take place using identical processing equipment, thereby simplifying process transfer, eliminating scale-up, and significantly reducing API consumption during the development process. The platform would ultimately have the potential to support a fast-response, low-inventory supply chain as well.

“This new oral solid-dose manufacturing paradigm will achieve significant cost savings and simplified technology transfer/scale-up from R&D to commercial manufacturing,” said Rod MacKenzie, senior vice-president and head of PharmaTherapeutics R&D at Pfizer, in the press release. “Using the same equipment for development, clinical supplies, and commercial production is expected to maximize efficiencies in manufacturing across the enterprise.”

Upon successful completion of this initiative, GEA and G-CON will work with Pfizer to deploy this complete solution of components and the POD facility globally. To more rapidly advance and develop this vision, Pfizer, GEA, and G-CON will further explore opportunities to partner with additional, interested companies.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here